Supplementary Information for:

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Fu et al.

	GM ^{pro}	GM ^{pro} -Boceprevir	GM ^{pro} -GC376	M ^{pro} - Bocenrevir	Mpro -GC376
PDB Code	7BRO	7BRP	7BRR	7068	7061
Data collection	/BRO	/ bitt	/ DRR	7005	7000
Space group	<u>C2</u>	P21	P21	C2	C2
Call dimensions	02	121	121	02	62
	112 42 54 26	17 27 52 55	55 45 00 02	07.22 80.25	100.00.70.61
<i>a</i> , <i>b</i> , <i>c</i> (A)	115.45, 54.20,	47.37, 55.55,	55.45, 99.02,	97.23, 80.25,	100.00, 79.01,
	44.96	113.//	59.58	54.48	51.85
α, β, γ (°)	90, 100.67, 90	90, 101.66, 90	90,108.54,90	90,116.72,90	90,114.71,90
Wavelength (A)	0.979	0.979	0.979	0.979	0.979
Resolution (Å)	50-2.20	50-1.80	50-1.40	50-1.60	50-2.00 (2.07-2.00)
	(2.07-2.00)	(1.86-1.80)	(1.50-1.40)	(1.66-1.60)	
R _{merge}	0.021 (0.057)	0.053 (0.611)	0.042 (0.1.085)	0.084 (0.792)	0.055 (0.227)
Ι / σΙ	70.7 (30.9)	28.4 (2.8)	43.2 (1.9)	22.3 (2.5)	34.4 (9.2)
CC1/2	0.998 (0.994)	0.998 (0.887)	0.998 (0.712)	0.991 (0.897)	0.993 (0.985)
Completeness (%)	99.6 (100.0)	99.5 (99.3)	100.0(100.0)	99.9 (100.0)	99.8 (100.0)
Redundancy	5.8 (5.9)	6.0 (5.9)	6.8 (6.6)	7.5 (7.6)	7.5 (7.5)
Refinement					
Resolution (Å)	25.83-2.00	27.57-1.80	29.03-1.40	48.67-1.60	43.26-2.00
No. reflections	18253	49507	108002	45351	24895
R _{work} / R _{free}	0.2533/0.2991	0.2156/0.2396	0.1887/0.1973	0.2075/0.2222	0.24.15/0.2512
No. atoms					
Protein	2341	4658	4733	2341	2329
Ligand/ion	0	74	58	37	29
Water	122	384	575	347	180
B-factors					
Protein	30.9	25.7	22.8	20.0	34.4
Ligand/ion		19.0	33.8	19.1	28.6
Water	34.3	29.1	32.4	26.3	30.9
R.m.s. deviations					
Bond lengths	0.002	0.003	0.006	0.007	0.002
(Å)					
Bond angles (°)	0.604	1.253	0.836	0.758	0.502
Ramachandran					
plot					
Favored (%)	96.64	97.99	98.16	97.66	97.32
Allowed (%)	3.36	2.01	1.84	2.34	2.68
Outliers (%)	0	0	0	0	0

Supplementary Table 1. Diffraction data and refinement statistics

*Values in parentheses are for highest-resolution shell.



Supplementary Figure 1. Sequence alignment of M^{pro} from SARS-CoV-2, SARS-CoV and MERS-CoV. The conserved catalytic residues (His41 and Cys145, in SARS-CoV-2) are indicated using red stars.



Supplementary Figure 2. the progress curve of peptide hydrolysis by SARS-CoV-2 M^{pro} and chymotrypsin.

a, Comparation of enzyme activity between GM^{pro} and M^{pro}. **b**, **c**, M^{pro} inhibition curve by Boceprevir and GC376. Slow inactivation of M^{pro} activity by Boceprevir and GC376 was observed from the curve. **d**, Bovine α -chymotrypsin inhibition curve by GC376 and Boceprevir. Source data are provided as a source data file.



Supplementary Figure 3. Structural details of the enzyme active site in M^{pro}. a, b, N-terminus structure and enzyme active site of GM^{pro} (colored by green) merged with native SARS-CoV-2 M^{pro} (colored by cyans, 6Y2E), native SASR virus M^{pro} (colored by yellow, 2H2Z) and GPLGS taged SASR virus M^{pro} (colored by purple, 1UJ1) crystal structure reported previously. **c,** GM^{pro} cocrystal structure (colored by yellow) with Boceprevir merged with M^{pro} cocrystal (colored by gray). **d,** GM^{pro} cocrystal structure with GC376 (colored by pink) merged with M^{pro} cocrystal (colored by gray).



Supplementary Figure 4. Both Boceprevir and GC376 show no cellular toxicity to Vero cells at test concentrations. Cytotoxicity of Boceprevir and GC376 in Vero cells were evaluated by CCK-8 assay. Error bars: mean \pm S.D. of three independent replicates. Source data are provided as a source data file.



Supplementary Figure 5. Images for the plaque-reduction assay

a, The inhibitory effect of Boceprevir in different concentration. **b**, The inhibitory effect of GC376 in different concentration. **c**, The inhibitory effect of Remdesivir in different concentration. **d**, Combine inhibitory effect of Remdesivir and GC376. **e**, DMSO means that 1% DMSO medium was incubated with Vero cells after virus infection. Virus means that medium without inhibitors or DMSO was incubated with Vero cells after virus infection. Mock means that the Vero cells was not infected with virus.



Supplementary Figure 6. Overall structures of SARS-CoV-2 M^{pro} complexed with Boceprevir or GC376.



Supplementary Figure 7. Electron density of SARS-CoV-2 M^{pro} complexed with Boceprevir (a) and GC376 (b). The panels show portions of 2Fo-Fc electron density maps for the two compounds contoured at 1.5 sigma.



Supplementary Figure 8. The detailed interactions of Boceprevir and GC376 bound to SARS-CoV-2 M^{pro}. Protein side chains and the inhibitors are shown as ball and sticks. Hydrogen bonds are shown as green dotted lines. The covalent bond between inhibitors and Cys145 residue is in purple. Spoked arcs represent nonbonded contacts. Figure is generated using LigPlot+ diagram¹.

Supplementary References

1. Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *J Chem Inf Model* **51**, 2778-2786 (2011).